# Opna Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/opna-bio

- Industry: Biotechnology
- Headquarters: Switzerland
- Website: www.opnabio.com
- Total disclosed funding: $38M
- Latest round: Series A (Nov 21, 2022)
- Investors on record: 3

## About

Based in Switzerland, Opna Bio SA is a clinical-stage biopharmaceutical company that specializes in the development of cancer therapy medications. Gideon Bollag (CEO), Joseph Schlessinger, and Douglas Hanahan are the co-founders of the company. In November 2022, Opna Bio SA raised USD 38 million in Series A funding from Longitude Capital, Northpond Ventures, and Menlo Ventures. As of 2022, the company also has an office in the US.

The company provides its lead clinical product, OPN-2853, a bromo- and extra-terminal (BET) domain inhibitor, which is in Phase 1/2 trial with ruxolitinib (Jakafi®) in myelofibrosis, a chronic bone marrow disorder. The firm’s other pipeline programmes include OPN-7486, OPN-6602, OPN-CD73, OPN-TEAD, and OPN-FMRP.

The organization intends to use the financing from November 2022 to create FMRP inhibitors for oncology research as well as a wide portfolio of clinical and preclinical oncology programmes that it has purchased from Plexxikon Inc.

## Funding rounds

- Series A, Nov 21, 2022, $38M — Menlo Ventures, Longitude Capital, Northpond Ventures

## Investors

- Menlo Ventures (https://capitalatlas.ai/funds/menlo-ventures) — Series A
- Longitude Capital (https://capitalatlas.ai/funds/longitude-capital) — Series A
- Northpond Ventures (https://capitalatlas.ai/funds/northpond-ventures) — Series A